Graviton
New York
About Graviton
Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases. TDI01, a highly selective, potent inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) is currently being studied in the United States for the treatment of idiopathic pulmonary fibrosis (IPF). Graviton anticipates entering human clinical studies in the U.S. in 2021.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $43.3M
- Last round: Series Unknown (Feb 2024)
- Website: graviton.bio
- Phone: +1 332-400-0444
Industries & Categories
Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/graviton-73642 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.